![](https://medcitynews.com/wp-content/uploads/sites/7/2019/01/GettyImages-858518736-1.jpg)
Ovid, Angelini sign Europe licensing deal worth up to $232.5M for rare disease drug
In exchange for a $20 million upfront payment and up to $212.5 million in milestones, Italy-based Angelini will gain exclusive development, manufacturing and commercialzation rights in Europe for OV101, a drug for Angelman syndrome.